NASDAQ:MRVI Maravai LifeSciences (MRVI) Stock Price, News & Analysis → Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad) Free MRVI Stock Alerts $8.96 -0.05 (-0.55%) (As of 05/7/2024 ET) Add Compare Share Share Today's Range$8.88▼$9.1050-Day Range$7.11▼$9.0152-Week Range$4.52▼$16.62Volume1.87 million shsAverage Volume2.49 million shsMarket Capitalization$2.25 billionP/E RatioN/ADividend YieldN/APrice Target$11.56 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Maravai LifeSciences alerts: Email Address Maravai LifeSciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.70 Rating ScoreUpside/Downside29.0% Upside$11.56 Price TargetShort InterestBearish5.93% of Float Sold ShortDividend StrengthN/ASustainability-1.23Upright™ Environmental ScoreNews Sentiment0.85Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.15) to ($0.11) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.93 out of 5 starsMedical Sector191st out of 903 stocksPharmaceutical Preparations Industry80th out of 420 stocks 3.4 Analyst's Opinion Consensus RatingMaravai LifeSciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 7 buy ratings, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageMaravai LifeSciences has only been the subject of 3 research reports in the past 90 days.Read more about Maravai LifeSciences' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.93% of the float of Maravai LifeSciences has been sold short.Short Interest Ratio / Days to CoverMaravai LifeSciences has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Maravai LifeSciences has recently increased by 23.83%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldMaravai LifeSciences does not currently pay a dividend.Dividend GrowthMaravai LifeSciences does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMaravai LifeSciences has received a 67.24% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Deoxyribonucleic acid (DNA)", "Microbiology laboratory services for research", and "Clinical research services for genetic diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for Maravai LifeSciences is -1.23. Previous Next 3.3 News and Social Media Coverage News SentimentMaravai LifeSciences has a news sentiment score of 0.85. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.38 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Maravai LifeSciences this week, compared to 3 articles on an average week.Search InterestOnly 2 people have searched for MRVI on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.MarketBeat Follows2 people have added Maravai LifeSciences to their MarketBeat watchlist in the last 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Maravai LifeSciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.22% of the stock of Maravai LifeSciences is held by insiders.Percentage Held by Institutions50.25% of the stock of Maravai LifeSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Maravai LifeSciences' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Maravai LifeSciences are expected to grow in the coming year, from ($0.15) to ($0.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Maravai LifeSciences is -9.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Maravai LifeSciences is -9.96, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMaravai LifeSciences has a P/B Ratio of 2.85. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Maravai LifeSciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceThe new financial threat that could wipe out millions…During the Internet boom, companies like Pets.com were supposed to be promising investments riding the wave of a new tech boom. But then they were gone within a blink of an eye. One of the most successful investors in history just stepped forward to say the same thing is about to happen to AI stocks.Pay close attention to this important video About Maravai LifeSciences Stock (NASDAQ:MRVI)Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.Read More MRVI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MRVI Stock News HeadlinesMay 6, 2024 | americanbankingnews.comMaravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Receives Consensus Recommendation of "Moderate Buy" from AnalystsMay 2, 2024 | americanbankingnews.comMaravai LifeSciences Target of Unusually Large Options Trading (NASDAQ:MRVI)May 8, 2024 | InvestorPlace (Ad)The Next Nvidia?The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.May 1, 2024 | americanbankingnews.comMaravai LifeSciences (MRVI) to Release Quarterly Earnings on WednesdayApril 30, 2024 | markets.businessinsider.comCraig-Hallum Keeps Their Buy Rating on Maravai Lifesciences Holdings (MRVI)April 30, 2024 | businesswire.comTriLink BioTechnologies® and Lonza Enter into Non-exclusive License and Supply Agreement for CleanCap® mRNA Capping TechnologyApril 18, 2024 | businesswire.comTriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance ProductionApril 17, 2024 | msn.comMaravai LifeSciences Holdings (MRVI) Price Target Increased by 6.78% to 9.98May 8, 2024 | InvestorPlace (Ad)The Next Nvidia?The Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.April 10, 2024 | globenewswire.comMaravai LifeSciences To Host Earnings Conference Call on Wednesday, May 8, 2024March 19, 2024 | finance.yahoo.comShould You Sell Maravai LifeSciences (MRVI)?March 12, 2024 | finance.yahoo.comMRVI Apr 2024 2.500 callMarch 12, 2024 | globenewswire.comMaravai LifeSciences Announces March 2024 Investor Conference ScheduleMarch 11, 2024 | finance.yahoo.comMRVI Apr 2024 2.500 putFebruary 26, 2024 | markets.businessinsider.comBuy Rating Affirmed for Maravai Lifesciences Amid Strong Financial Performance and Growth OutlookFebruary 24, 2024 | uk.news.yahoo.com300 from RNAS Culdrose join largest NATO exercise since the Cold WarFebruary 24, 2024 | finance.yahoo.comMaravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Just Released Its Annual Results And Analysts Are Updating Their EstimatesFebruary 23, 2024 | marketwatch.comMaravai LifeSciences Shares Rise 65% After 4Q ResultsFebruary 23, 2024 | markets.businessinsider.comSmall-Cap Maravai LifeSciences' Q4 Outperforms Expectations, Analyst shows Optimism Around 2024 GuidanceFebruary 23, 2024 | finance.yahoo.comMaravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Q4 2023 Earnings Call TranscriptFebruary 23, 2024 | markets.businessinsider.comMaravai Lifesciences Holdings: Poised for Growth with Strong Q4 Performance and Promising FY2024 OutlookFebruary 23, 2024 | fool.comMaravai LifeSciences (MRVI) Q4 2023 Earnings Call TranscriptFebruary 22, 2024 | msn.comMaravai 2024 revenue guidance propels stock 20% higherFebruary 22, 2024 | msn.comMaravai LifeSciences Holdings GAAP EPS of -$0.80 misses by $0.78, revenue of $74.14M beats by $9.8MFebruary 22, 2024 | finance.yahoo.comMaravai LifeSciences Holdings Inc (MRVI) Faces Net Loss in 2023 Despite Revenue OutperformanceFebruary 22, 2024 | globenewswire.comMaravai LifeSciences Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 21, 2024 | finance.yahoo.comTriLink BioTechnologies® Solidifies IP Position with Awarded Patents for CleanCap® Capping Technology in China and CanadaSee More Headlines Receive MRVI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Maravai LifeSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/22/2024Today5/07/2024Next Earnings (Confirmed)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MRVI CUSIPN/A CIK1823239 Webwww.maravai.com Phone858-546-0004FaxN/AEmployees650Year FoundedN/APrice Target and Rating Average Stock Price Target$11.56 High Stock Price Target$17.00 Low Stock Price Target$7.00 Potential Upside/Downside+29.0%Consensus RatingModerate Buy Rating Score (0-4)2.70 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($0.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-119,030,000.00 Net Margins-41.19% Pretax Margin213.79% Return on Equity-1.31% Return on Assets-0.55% Debt Debt-to-Equity Ratio0.70 Current Ratio8.00 Quick Ratio7.41 Sales & Book Value Annual Sales$288.95 million Price / Sales7.80 Cash Flow$0.09 per share Price / Cash Flow94.72 Book Value$3.14 per share Price / Book2.85Miscellaneous Outstanding Shares251,400,000Free Float250,847,000Market Cap$2.25 billion OptionableOptionable Beta0.03 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Carl W. Hull (Age 65)Co-Founder & Executive Chairman Comp: $617.67kMr. William E. Martin III (Age 49)Chief Executive Officer Comp: $987.86kMr. Kevin M. Herde (Age 52)Executive VP & CFO Comp: $548.62kDr. Peter Michael Leddy Ph.D. (Age 61)Executive VP & Chief Administrative Officer Comp: $583.39kMs. Christine Dolan (Age 56)Executive VP & GM of Cygnus Technologies Comp: $536.63kMr. Andrew Burch (Age 55)President of Nucleic Acid Production Comp: $425.15kMs. Debra HartSenior Director of Investor RelationsMr. Kurt Oreshack (Age 43)Executive VP, General Counsel & Secretary Comp: $701.4kMs. Rebecca BuzzeoExecutive VP & Chief Commercial OfficerDr. Kate E. Broderick Ph.D.Chief Innovation OfficerMore ExecutivesKey CompetitorsDyne TherapeuticsNASDAQ:DYNGeronNASDAQ:GERNArdelyxNASDAQ:ARDXArvinasNASDAQ:ARVNRocket PharmaceuticalsNASDAQ:RCKTView All CompetitorsInstitutional OwnershipQRG Capital Management Inc.Bought 1,796 shares on 5/8/2024Ownership: 0.007%Headlands Technologies LLCBought 4,882 shares on 5/8/2024Ownership: 0.002%12 West Capital Management LPBought 1,600,000 shares on 5/7/2024Ownership: 5.252%Sei Investments Co.Sold 3,643 shares on 5/7/2024Ownership: 0.026%SG Americas Securities LLCSold 41,003 shares on 5/7/2024Ownership: 0.021%View All Institutional Transactions MRVI Stock Analysis - Frequently Asked Questions Should I buy or sell Maravai LifeSciences stock right now? 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Maravai LifeSciences in the last year. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MRVI shares. View MRVI analyst ratings or view top-rated stocks. What is Maravai LifeSciences' stock price target for 2024? 10 equities research analysts have issued 1-year target prices for Maravai LifeSciences' shares. Their MRVI share price targets range from $7.00 to $17.00. On average, they predict the company's share price to reach $11.56 in the next twelve months. This suggests a possible upside of 29.0% from the stock's current price. View analysts price targets for MRVI or view top-rated stocks among Wall Street analysts. How have MRVI shares performed in 2024? Maravai LifeSciences' stock was trading at $6.55 at the beginning of the year. Since then, MRVI shares have increased by 36.8% and is now trading at $8.96. View the best growth stocks for 2024 here. Are investors shorting Maravai LifeSciences? Maravai LifeSciences saw a increase in short interest in the month of April. As of April 15th, there was short interest totaling 6,340,000 shares, an increase of 23.8% from the March 31st total of 5,120,000 shares. Based on an average trading volume of 2,740,000 shares, the days-to-cover ratio is currently 2.3 days. Approximately 5.9% of the shares of the company are short sold. View Maravai LifeSciences' Short Interest. When is Maravai LifeSciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our MRVI earnings forecast. How can I listen to Maravai LifeSciences' earnings call? Maravai LifeSciences will be holding an earnings conference call on Wednesday, May 8th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link. How were Maravai LifeSciences' earnings last quarter? Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) issued its quarterly earnings data on Thursday, February, 22nd. The company reported ($0.05) earnings per share for the quarter, missing the consensus estimate of ($0.04) by $0.01. The company had revenue of $74.14 million for the quarter, compared to analysts' expectations of $62.99 million. Maravai LifeSciences had a negative trailing twelve-month return on equity of 1.31% and a negative net margin of 41.19%. What ETF holds Maravai LifeSciences' stock? Morningstar US Small Growth holds 10,940 shares of MRVI stock, representing 4.94% of its portfolio. What guidance has Maravai LifeSciences issued on next quarter's earnings? Maravai LifeSciences issued an update on its FY 2024 earnings guidance on Thursday, February, 22nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $265.0 million-$285.0 million, compared to the consensus revenue estimate of $261.0 million. When did Maravai LifeSciences IPO? Maravai LifeSciences (MRVI) raised $1.3 billion in an initial public offering (IPO) on Friday, November 20th 2020. The company issued 50,000,000 shares at $24.00-$27.00 per share. Morgan Stanley, Jefferies and Goldman Sachs served as the underwriters for the IPO and BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel, Keybanc Securities, Academy Securities, Loop Capital Markets, Penserra Securities and Tigress Financial Partners were co-managers. Who are Maravai LifeSciences' major shareholders? Maravai LifeSciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include 12 West Capital Management LP (5.25%), Principal Financial Group Inc. (0.16%), Jennison Associates LLC (0.16%), Sei Investments Co. (0.03%), Capstone Investment Advisors LLC (0.02%) and SG Americas Securities LLC (0.02%). How do I buy shares of Maravai LifeSciences? Shares of MRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MRVI) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsShocking: One AI startup's revenue could surge 4,735%Manward PressAI “wealth window” is closing June 25thParadigm PressStock-Picking AI Predicts #1 Stock of 2024AltimetryThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorThe #1 lithium battery stock to have on your radar in 2024!Smallcaps DailyElon Musk Secret Crypto Plot ExposedCrypto 101 MediaForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maravai LifeSciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.